Use of specific dose of fondaparinux sodium for the treatment of acs
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 9, 2004
app pub date -
Apr 8, 2004
filing date -
Nov 13, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The the use of a dose of 2.5 mg of the pentasaccharide methyl O-(2-deoxy-2-sulfoamino-6-O-sulfo-.alpha.-D-glucopyranosyl)-(1.fwdarw.4)--O-(.beta.-D-glucopyranosyl uronic acid)-(1.fwdarw.4)-O-(2-deoxy-2-sulfoami-no-3,6-di-O-sulfo-.alpha.-D-glucopyranosyl)-(1.fwdarw.4)-O-(2-O-sulfo-.alp-ha.L-idopyranosyl uronic acid)-(1.fwdarw.4)-2-deoxy-2-sulfoamino-6-O-sulfo--.alpha.-D-glucopyranoside decasodium salt for the treatment of Acute Coronary Syndromes (ACS).
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully